BioMedNewsBreaks

TuesdayNov 09, 2021 10:39 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release Q2 2021 Financial Results, Host Call

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is planning to release its Q2 2021 financial report on Nov. 15, 2021. The report will cover the period ended Sept. 30, 2021. The company  is also planning on hosting a conference call and webcast the same day, which is scheduled to begin at 4:30 p.m. EST. The call will be hosted by Cybin CEO Doug Drysdale and will provide an overview of the financial results along with relevant business updates. In addition, Drysdale and other team members will answer questions during the call. Those who…

Continue Reading

MondayNov 08, 2021 12:21 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s presentation will begin at 3:30 p.m. ET on Nov. 17. Case will provide an overview of the company, including a look at how Anpac Bio is democratizing early cancer screening and detection; he will also be available for one-on-one meetings with qualified investors. The company…

Continue Reading

MondayNov 08, 2021 11:00 am

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Demonstrates Numerous Advantages over Oral Psilocybin for Treatment of Mental Health

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive CYB003 pre-clinical findings. According to the update, the findings demonstrate multiple advantages for Cybin’s newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental health care, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Cybin’s CEO Doug Drysdale in the news release. “Cybin has always strived to develop safer and more effective therapies for patients, which…

Continue Reading

ThursdayNov 04, 2021 10:46 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Panel Discussion at Wonderland: Miami

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will participate in Wonderland: Miami, presented by Microdose. The event is set to take place Nov. 8-9, 2021, in Miami, Florida. Tryp’s chairman and CEO Greg McKee will participate in a panel discussion entitled, “Developing Psychedelic Medicine Beyond What We Already Know,” beginning at 2:40 p.m. ET on Nov. 8. In the discussion, McKee will highlight Tryp's leading-edge work with synthetic psilocybin for chronic pain and other indications. To view the full press release, visit https://ibn.fm/S87TX…

Continue Reading

WednesdayNov 03, 2021 11:13 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids, today announced its filing of an international patent application demonstrating neuroprotection and enhanced neuronal function using a rare cannabinoid for the potential treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s and others. The Patent Cooperation Treaty (“PCT”) application, entitled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids,” specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in a population of affected neurons. Further, the PCT application demonstrates the subject cannabinoid compound can also be used…

Continue Reading

WednesdayNov 03, 2021 10:53 am

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Patent Covering Formulations Featuring Nanoemulsion

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced that it has filed a technology patent protecting the creation of formulations that use nanoemulsion technology. The formulations aim to enhance, stabilize and make repeatable properties of ingredients from traditional medicine. According to the announcement, the patent is intended to cover formulations that have received GRAS-certification from the U.S. Food and Drug Administration. Nanoemulsion technology is vital to Mydecine’s active drug development. “This patent filing marks a key milestone for Mydecine’s drug development pipeline in…

Continue Reading

TuesdayNov 02, 2021 2:45 pm

BioMedNewsBreaks – Why Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Is ‘One to Watch’

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Founded in 2020 based on delivering to significant unmet need in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other disorders. “The company currently has four lead drug candidates, which include various enhancements such as improved controllability, delivery mechanisms, safety, stability and shelf-life. The drug candidates are in clinical trials or in pre-trial stage as potential treatments to aid…

Continue Reading

TuesdayNov 02, 2021 11:03 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND Application to Evaluate Clinical Candidate in Phase 2a Trial in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its clinical candidate, TRP-8802, in a phase 2a clinical trial. Conducted with Kevin Boehnke, Ph.D. from the University of Michigan, the trial seeks to investigate safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia in collaboration with the University of Michigan and will evaluate the company's oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy.…

Continue Reading

MondayNov 01, 2021 11:39 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Way Through Unique Psychedelic Drug Development Focus

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is nearing the launch of a phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (“PWS”), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction. Tryp also plans to execute phase 2b clinical trials for its proprietary psychedelic candidate TRP-8803 to evaluate its ability to penetrate the natural blood-brain barrier and effectively alleviate pain and addiction concerns, including targets for phantom limb pain and fibromyalgia. “Tryp’s product development moves beyond…

Continue Reading

FridayOct 29, 2021 1:38 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging CDA Technology for Critical Early Cancer Detection

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, since 2015 has commercially proven out its concepts through the development and sale of its cancer detection technology, Cancer Differentiation Analysis (“CDA”) for early detection of pre-cancerous disease and cancer. “The company has published numerous reports of clinical study results at major conferences, including ACSO conferences, and has been awarded over 100 patents globally. AnPac Bio is now able to make the claim that it is saving lives on a daily basis by detecting 26 different types of cancer very early, through the tens of…

Continue Reading